Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited , and Seattle Genetics, Inc. today announced the initiation of an international phase 3 clinical trial evaluating ADCETRIS as part of a frontlin…
BOTHELL, Wash., Oct. 29, 2012 /PRNewswire/ — BioLife Solutions , Inc. (OTCBB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation …
People waiting for a lung transplant face a big problem– the vast majority of donor lungs are too damaged to be used. The new technology, called XVIVO (for ex-vivo, meaning outside the body), allows doctors to treat and recondition donor lungs that wo…
What's worse than diarrhea? Recurring diarrhea, not to mention abdominal pain and a colon so inflamed it could kill you.
JERUSALEM, Oct. 24, 2012 /PRNewswire/ — Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by …
"Wildcat" Chris Harris, a multiple-time tag team champion in TNA Wrestling with James Storm, revealed on Facebook that he was diagnosed with multiple myeloma late last year, a life-threatening cancer. He underwent a stem-cell transplant and w…
"Wildcat" Chris Harris revealed on Facebook that he was diagnosed with multiple myeloma late last year, a life-threatening type of cancer. He underwent a stem-cell transplant and will receive high-dose chemotherapy on Tuesday.
Medical researchers conducted a two-year clinical trial comparing two-year survival probabilities for patients transplanted with peripheral blood stem cells or bone marrow stem cells from unrelated donors.
Claudio Anasetti, M.D., chair of the Department of Blood & Marrow Transplant at Moffitt Cancer Center, and colleagues from 47 research sites in the Blood and Marrow Transplant Clinical Trials Network conducted a two-year clinical trial comparing two-ye…
( H. Lee Moffitt Cancer Center & Research Institute ) Claudio Anasetti, M.D., chair of the Department of Blood & Marrow Transplant at Moffitt Cancer Center, and colleagues from 47 research sites in the Blood and Marrow Transplant Clinical Trials Networ…